Key Insights

Highlights

Success Rate

78% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

8.7%

2 terminated out of 23 trials

Success Rate

77.8%

-8.7% vs benchmark

Late-Stage Pipeline

17%

4 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed with results

Key Signals

1 with results78% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (6)
P 1 (1)
P 2 (4)
P 3 (4)

Trial Status

Completed7
Recruiting6
Unknown4
Not Yet Recruiting2
Terminated2
Active Not Recruiting1

Trial Success Rate

77.8%

Benchmark: 86.5%

Based on 7 completed trials

Clinical Trials (23)

Showing 20 of 20 trials
NCT07374874RecruitingPrimary

A Cohort Study on the Association Between the ANS Function and Acute GvHD

NCT06393660UnknownPrimary

Treatment Use of the CliniMACS® CD34 TCR Alpha/Beta for Allogenic Transplant (Expanded Access Use)

NCT07157514Phase 2Not Yet Recruiting

Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML

NCT05967130Phase 3Terminated

Treatment Chronic UTI Post Kidney Transplant

NCT07013370Recruiting

Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT06066957Phase 2Recruiting

Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

NCT03636412Not ApplicableCompletedPrimary

Improving Frailty With a Rigorous Ambulation Intervention in Lung Transplant Patients

NCT06950788Recruiting

Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant

NCT05798286Not ApplicableActive Not Recruiting

Quantra® System With the QPlus® Cartridge in Double-lung Transplantation

NCT06888479Phase 3Not Yet RecruitingPrimary

Optimal Timing of Hepatitis B Vaccination After Transplants

NCT05600855Phase 2CompletedPrimary

Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model

NCT05599256Phase 2RecruitingPrimary

Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model

NCT03769441Phase 3Completed

Effect of Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation

NCT06208137Not ApplicableRecruitingPrimary

Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.

NCT03811873Not ApplicableCompleted

Assessment of Vertebral Fracture Risk for First Time Liver Transplant Candidates

NCT05629923Completed

EVALUATION OF DIFFERENT PROPHYLACTIC INTERVENTIONS TOWARD COVID-19 IN SOLID ORGAN TRANSPLANT PATIENTS

NCT04985409Not ApplicableCompleted

Stepping Up: A Trial of Activity Monitoring Devices in Patients Undergoing Autologous Stem Cell Transplant

NCT05441436UnknownPrimary

Neuropsychological and Biopsychosocial Evolution During Pediatric Transplantation: Pre/Post-stages and at 6 Months

NCT04756622Phase 3Unknown

N-acetyl Cysteine for the Prevention of Oral Mucositis After Autologous Hematopoietic Cell Transplantation.

NCT03399227Withdrawn

Liver Transplantation: Skeletal Effects

Scroll to load more

Research Network

Activity Timeline